Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Device of Tomorrow Capital is an early-stage investment fund based in the United States, specializing in medical technology. The firm focuses on pre-seed, seed, and Series A stages, supporting entrepreneurs who are making significant changes in healthcare. They have a portfolio of 8 companies, emphasizing advancements in healthcare technology.
This firm invests in breakthrough innovations within the medical technology sector, particularly in artificial intelligence, robotics, and biotechnology. Device of Tomorrow Capital seeks to support advancements that are reshaping healthcare in the United States, targeting early-stage companies that are developing transformative solutions.
Notable portfolio companies include: Carlsmed, the first company using AI and 3D printing for customized treatment plans for adult spinal deformities; Telesair, which develops scalable, AI-enabled blood tests for early cancer detection; Andromeda, focused on a radiotherapy solution that reduces costs and side effects; WearLinq, offering FDA-cleared endovascular therapy navigation technology; Paloma, a wireless, catheter-free urodynamic monitoring system; iCardio.AI, an AI diagnostic tool for early detection of Alzheimer's Disease; Leo Cancer Care, innovating in personalized healthcare with advanced surgical planning solutions; and Aureka Biotechnologies, developing a therapeutic discovery platform.
Email henry.yan@luminor.us with your deck to pitch Device of Tomorrow Capital.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.